Role of Axumin PET Scan in Germ Cell Tumor (TESTPET)

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Active, not recruiting

Conditions

Testicular Choriocarcinoma
Testicular Cancer
Germ Cell Cancer, Nos
Testicular Diseases
Germ Cell Neoplasm of Retroperitoneum
Testicular Neoplasms
Germ Cell Cancer Metastatic
Testis Cancer
Germ Cell Tumor
Germ Cell Tumor of Testis
Testicular Yolk Sac Tumor
Germ Cell Tumor, Testicular, Childhood
Testicular Germ Cell Tumor

Treatments

Drug: Axumin PET scan

Study type

Observational

Funder types

Other

Identifiers

NCT03426865
STU 032017-051

Details and patient eligibility

About

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

Full description

Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We will correlate histopathologic outcomes from the RPLND specimen and clinical outcomes of recurrence during follow-up to identify the accuracy of anti-18F-FACBC PET/CT in these settings.

Enrollment

10 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to undergo primary RPLND or post-chemotherapy RPLND
  • Patients must be over 18 years old and capable and willing to provide informed consent.
  • Medically stable as judged by patient's physician.
  • Life expectancy must be estimated at > 6 months.
  • Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age >70 years).
  • Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be asked if they have problems or issues with lying flat

Exclusion criteria

  • Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are NOT eligible.
  • Patients with liver failure are NOT eligible.
  • Patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18F-FACBC PET/CT scan are NOT eligible

Trial design

10 participants in 1 patient group

Axumin PET scan
Description:
Only one arm is being evaluated--the arm receiving PET scan
Treatment:
Drug: Axumin PET scan

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems